Objective. Reactive oxygen species have been implicated in the pathogenesis of inflammatory and vascular disease. We have undertaken a controlled trial to evaluate probucol, a synthetic antioxidant, as a potential therapy for Raynaud's phenomenon.
Raynaud's phenomenon manifests as episodic cold-or increased risk of developing an autoimmune rheumatic disease and they have been designated 'autoimmune stress-induced vasospasm affecting the extremities, and Raynaud's' [2] . can cause major disability in its severe forms [1] .
The pathophysiology of Raynaud's phenomenon is Although most often occurring in otherwise healthy complex and its aetiopathogenic relationship to any coindividuals (primary Raynaud's phenomenon), it is genexistent connective tissue disease is unclear [3] . Reactive erally more severe when associated with an underlying oxygen species (including free radicals) have been implicautoimmune rheumatic disease. Raynaud's is often a ated in the development of a number of rheumatic feature of systemic sclerosis (SSc), polymyositis or sysdiseases [4] , and are also potential mediators of the temic lupus erythematosus, and when associated with endothelial cell injury which is characteristic of secondthese conditions is termed secondary Raynaud's pheary Raynaud's [5] . One mechanism by which these nomenon. A third subtype is recognized in sufferers who reactive oxygen species might mediate endothelial cell have abnormal nailfold capillaries and positive antiinjury is through their oxidative effect on plasma liponuclear antibodies, but no other clinical features of a proteins [6 ] . Oxidized lipoproteins, especially lowdefined connective tissue disease. Such patients are at density lipoproteins (LDLs), may trigger endothelial cell damage in SSc [7] , as well as in more prevalent vascular pathologies such as atherosclerosis [8] . It has been Methods capsules, and probucol in 250 mg tablets, and patients Patients were instructed to take one tablet twice daily during the treatment period. To minimize weather and seasonal Raynaud's phenomenon was defined by triphasic colinfluences on Raynaud's symptoms, the study took place our changes (pallor-cyanosis-suffusion) affecting the over 4 months during one winter. extremities, precipitated by cold or emotion, and occurring at least once on most days. Patients with Raynaud's Symptom diaries phenomenon (n = 40) were enrolled into the study, Symptom severity was self-assessed by patients using a which was approved by the Royal Free Hospital Ethical visual analogue scale (0-10) for the most severe attack Practices Sub-committee. Half of the patients had suffered each assessment day, and the number of attacks Raynaud's phenomenon in association with SSc. Of on that day was also recorded. The primary clinical end these, the majority (n = 15) had limited cutaneous SSc; points were a change in the mean daily severity or the remainder (n = 5) fulfilled the criteria of the diffuse frequency of Raynaud's attacks between the baseline 2 cutaneous subset [12] . Of the non-SSc patients, 15 had week period and the final 2 weeks of treatment. Before primary Raynaud's phenomenon, defined by the absence commencing the study, subjects received careful training of any clinical features of a connective tissue disease, in completion of the symptom diary from an experienced positive autoimmune serology or significantly abnormal investigator (HW ). Although this was not a blinded nailfold capillaroscopic appearance [13] . The remaining trial, patients were given their therapy labelled as 'Study patients (n = 5) had no clinical evidence of rheumatic Drug', which did not state into which arm of the trial disease, but were found to have positive antinuclear they had been randomized, and it was clearly explained antibodies and abnormal nailfold capillaroscopic that they were equally likely to receive either probucol appearance, and were categorized as 'autoimmune or nifedipine. Raynaud's'. There were eight current (three with SSc) and eight ex-smokers (four with SSc) in the study group.
Isolation of LDL and measurement of lag times for Patients were randomized to receive either probucol or oxidation nifedipine, with half of the SSc cases entering each Blood (20 ml non-fasting) was drawn into tubes contreatment arm. The clinical and demographic features taining 63 m EDTA, as an anticoagulant, and 46 m of each treatment group are summarized in Table 1. DTPA, which specifically chelates free transition metal Study design and drug formulation ions that may propagate free radical attack on lipoprotein lipids. Plasma was obtained by centrifugation of This was a randomized parallel group study. Nifedipine is widely prescribed as a treatment for Raynaud's phewhole blood at 3000 g for 11 min. Plasma density was adjusted to 1.3 g/ml and the LDL fraction was isolated nomenon and was chosen for the control arm of the study. It was felt that an active-treatment control arm by centrifugation underlying a saline solution [7] . The LDL band was removed, concentrated (Amicon would facilitate recruitment into the study and provide Concentrator) and the purity of the LDL fraction was of 32% from baseline in Raynaud's severity and of 20% in the frequency of attacks over the treatment period confirmed by SDS-PAGE [14] . Oxidation lag time was defined as the duration of the lag phase before LDL for patients receiving probucol ( Fig. 1 ), but no significant change for the nifedipine treatment group. oxidation occurred following addition of 1.6 m Cu2+ to the LDL solution (0.25 g protein/l ). Oxidation was Improvement in symptoms on probucol was accompanied by a significant increase in lag time for lipoprotein detected by increased absorbency at 234 nm, indicating the formation of conjugated diene intermediates generoxidation (mean 164% of pre-treatment time) and was also associated with a modest, though highly significant, ated in the oxidative attack of polyunsaturated fatty acids from the abstraction of hydrogen [15] . reduction in serum cholesterol (Fig. 2) . Furthermore, unpaired comparison of mean change for each treatment Biochemical variables group confirmed statistically significant differences for oxidation lag time (P = 0.05) and change in cholesterol Blood levels of micronutrient antioxidants were measured using validated assay protocols. Thus, vitamin E level (P = 0.01), although comparison of the mean change in Raynaud's attack frequency or severity did [16 ] and vitamin C [17] were quantified at baseline and completion of the study by high-pressure liquid chromanot reach statistical significance (P = 0.25 and P = 0.09, respectively). Levels of vitamins E and C did not change tography (HPLC ). Plasma lipid levels (triglyceride and cholesterol ) were also measured by standard enzymatic significantly in either treatment arm. Baseline variables were compared between patients methods. To confirm compliance, probucol was measured by HPLC, although the results were not made with SSc-associated Raynaud's and those without clinical features of a defined connective tissue disease available to investigators until the study was complete.
(primary or autoimmune Raynaud's). These data are Statistical analysis summarized in Table 3 . There were some statistically significant differences between these two groups, in Pre-and post-treatment values for each variable were compared within groups using Student's paired t-test, keeping with previous observations. Thus, the patients with SSc had significantly greater LDL oxidation lag to assess the effect of therapy. Comparisons between groups employed Student's unpaired t-test. Probability time and lower levels of vitamin C. There was also a significantly greater triglyceride level in the SSc group, values are given for each test and P < 0.05 was taken as statistically significant. although levels in both groups were within the normal reference range. Mean Raynaud's attack severity and frequency were somewhat higher in the SSc patients Results than in those without SSc, but this difference was not statistically significant. When the SSc and non-SSc Overall, there was a statistically significant improvement in Raynaud's symptoms in patients treated with probupatients were separated for subgroup analysis of treatment effect, the changes noted above were less marked, col, but not in the control group. Analysis of treatment effect was on an intention-to-treat basis, comparing although the same trends were observed for Raynaud's attack severity and frequency ( Table 4) . Mean changes values at baseline with those after the 12 week treatment period for each variable. These data are given in Table  were F. 1. Improvement in Raynaud's attack severity and frequency following probucol treatment. Mean Raynaud's attack severity and frequency were determined from the self-reported diaries. Baseline values were compared with those recorded during the final 2 weeks of probucol treatment (500 mg/day) using Student's paired t-test analysis (n = 17).
F. 2. Probucol treatment increases LDL oxidation lag time and reduces serum cholesterol levels. Oxidation lag times for LDL from patients taken before and after 12 weeks of probucol administration are shown. Lag time was determined spectrophotometrically and was significantly greater after treatment with probucol. There was also a modest, but statistically significant, reduction in total serum cholesterol in these patients. Analysis by Student's paired t-test (n = 17).
swelling. These were severe enough to require cessation eity of these conditions, with the likelihood that different subsets of patients may respond differently to particular of treatment in three cases. Probucol caused headache and nausea in four patients, and two of these individuals therapies, and is compounded by difficulties in objective serial assessment of clinical severity. Probably the most stopped treatment before completion of the 12 week study period. There were no major adverse events in widely used assessment technique for Raynaud's phenomenon is the self-reported symptom diary. However, either study arm.
its reliability depends on good and consistent patient education, preferably with blinding of the patient and Discussion the assessor in interventional studies. Formal blinding was not possible in this study due to the different Clinical trials are recognized to be difficult in Raynaud's phenomenon and SSc [18] . This reflects the heterogenformulations of the two drugs. It is well recognized that of SSc, and has been proposed as a potential mechanistic link between Raynaud's phenomenon and SSc [20] . The there is often a substantial placebo response in role of reactive oxygen species in the generation of Raynaud's therapies and this was minimized by using a Raynaud's symptoms is not directly addressed in our parallel-group controlled-trial design with two active study, but such a link is plausible and our results provide treatment arms. Though statistically significant, the clinindirect support for this. However, it is important to ical improvement for probucol-treated patients was remember that lipoprotein oxidation in vitro in a Cu2+ modest, and it may be advisable to blind future trials oxidizing environment is a somewhat artificial system. formally to reduce potential bias further. Seasonal influIt is also likely that some probucol is retained within ences are also a possible problem in Raynaud's trials, lipoproteins during isolation and so assay results may since most patients experience more frequent and severe not directly reflect in vivo antioxidant activity. attacks during the winter. To minimize this effect, our It is possible that probucol modulates Raynaud's study was undertaken over a single winter period.
symptoms in an entirely different way, e.g. through Although this was a small trial with a relatively short direct protection from endothelial cell damage. Such a treatment duration, our findings support the hypothesis mechanism could also explain its beneficial effects in that systemic administration of a potent synthetic antimacrovascular disease, as discussed below. It would be oxidant could be beneficial in Raynaud's phenomenon.
interesting to address this possibility in future studies The efficacy of probucol as an antioxidant is illustrated examining changes in the levels of circulating markers by the increase in oxidation lag time of lipoprotein of endothelial cell perturbation during probucol therapy. fractions from patients after treatment. It is interestMarkers of endothelial cell perturbation, such as von ing that nifedipine had no demonstrable effects on Willebrand Factor, E-selectin, endothelin-1 and thromRaynaud's symptoms since this agent is widely used for bomodulin, have been measured in several crossthis condition [19] . One explanation could be the low sectional [21] and longitudinal studies [22, 23] in dose used in this study, selected to minimize side-effects Raynaud's phenomenon and SSc, and correlation with which might have increased the withdrawal rate. Also, clinical severity has been reported. However, interpretthe mean severity and frequency of Raynaud's attacks were somewhat greater at baseline for the probucolation of these markers is complicated by the heterogen- eous nature of these conditions, by differential involvefurther evaluation of probucol is necessary to define its therapeutic potential in these diseases properly. ment of various microvascular beds and by the difficulty of distinguishing between the relative contribution of inflammatory, fibrotic or vasospastic disease processes
